Monoclonal Antibodies Market Size, Share, Opportunities, And Trends By Indication (Inflammatory Disease, Cancer, Microbial Disease, Others), By Source (Humanized, Human, Chimeric, Murine), By Application (Diagnostic, Therapeutic, Others), By End-User (Hospitals & Clinics, Research Laboratories), And By Geography - Forecasts From 2025 To 2030

Monoclonal Antibodies Market Size:

The Monoclonal Antibodies Market is expected to grow from US$201.429 billion in 2025 to US$340.700 billion in 2030, at a CAGR of 11.08%.

The immune system naturally produces antibodies in response to an infection. A monoclonal antibody is a molecule designed to enhance the body’s natural immune system response against an invader, such as cancer or an infection. It is developed in a laboratory and hence comes under man-made drugs. Monoclonal antibodies are created to specifically target an essential part of the infectious process, and therefore, they have an advantage over other types of treatment for infections. It is created by exposing a white blood cell to a particular viral protein. It is then cloned to mass-produce antibodies, which target that virus. The monoclonal antibodies are developed to treat several viral infections, such as Ebola and rabies. They were widely used during the COVID-19 pandemic, as the clinical trials proved that the antibodies are effective in reducing the severity.

Monoclonal Antibodies Market Growth Drivers:

• Increased demand for monoclonal antibodies

According to the World Health Organization, around 10 million people died due to cancer worldwide in 2020. For cancer treatment, monoclonal antibodies are significantly helpful, therefore, there is an increasing need for affordable cancer therapies. Moreover, during the COVID-19 pandemic, a large number of monoclonal antibodies’ clinical trials took place in order to develop novel drug therapy, as well as a wide range of product approvals were made for emergency use in COVID-19 treatment.

With its growing demand, the market players have a strong focus on the development as well as the discovery of monoclonal antibody therapeutics. The step has been taken to offer highly specific treatment for complex and severe diseases. Furthermore, it will stimulate the monoclonal antibodies market growth potential.

Monoclonal Antibodies Market Geographical Outlook:

• North America is expected to hold a significant share during the anticipated period

North American countries have a well-developed healthcare infrastructure. However, the high intake of alcohol and junk/fast food culture in this region is leading to obesity and also putting the population at a high risk of being infected with cancer. According to a study by American Cancer Society researchers in 2019, there were at least 42% of newly diagnosed cancers in the US – about 740,000 cases in 2019 were potentially avoidable. The study also said that out of the newly diagnosed cancer patient, 19% of all cancers are caused by smoking, and 18% are caused by to lack of physical activity, excess alcohol, and junk food consumption, which leads to excess body weight and poor nutrition.

Furthermore, new vaccines/drugs are being developed to help in the treatment of cancer patients. For example, in October 2022, Amneal Pharmaceuticals announced the launch of bevacizumab-maly (Alymsys) in the United States. The drug is a biosimilar reference of bevacizumab (Avastin, Genentech).  Bevacizumab-maly is developed by mAbxience. The drug will be useful in the treatment of metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Monoclonal Antibodies Companies:

• AbbVie, Inc.
• Novartis AG
• Bristol Myers Squibb
• F.Hoffmann-La Roche Ltd
• Johnson & Johnson Services, Inc.

Monoclonal Antibodies Market Segmentation:

• By Indication
  • Inflammatory Disease
  • Cancer
  • Microbial Disease
  • Others
• By Source
  • Humanized
  • Human
  • Chimeric
  • Murine
• By Application
  • Diagnostic
  • Therapeutic
  • Others
•  By End-User
  • Hospitals & Clinics
  • Research Laboratories
• By Geography
  • North America
    • USA
    • Canada
    • Mexico 
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Thailand
    • Taiwan
    • Others

---

1. INTRODUCTION

1.1. Market Overview

1.2. COVID-19 Scenario

1.3. Market Definition

1.4. Market Segmentation

 

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Assumptions

 

3. EXECUTIVE SUMMARY

3.1. Research Highlights

 

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

 

5. MONOCLONAL ANTIBODY MARKET, BY INDICATION

5.1. Introduction

5.2. Inflammatory Disease

5.3. Cancer

5.4. Microbial Disease

5.5.  Others

 

6. MONOCLONAL ANTIBODY MARKET, BY SOURCE

6.1. Introduction

6.2. Humanized

6.3. Human

6.4. Chimeric

6.5. Murine

 

7. MONOCLONAL ANTIBODY MARKET, BY Application

7.1. Introduction

7.2. Diagnostic

7.3. Therapeutic

7.4. Others

 

8. MONOCLONAL ANTIBODY MARKET, BY END-USER

8.1. Introduction

8.2. Hospitals & Clinic

8.3. Research Labourites

 

9. MONOCLONAL ANTIBODY MARKET, BY GEOGRAPHY

9.1. Introduction

9.2. North America

9.2.1. USA

9.2.2. Canada

9.2.3. Mexico 

9.3. South America

9.3.1. Brazil

9.3.2. Argentina

9.3.3. Others

9.4. Europe

9.4.1. Germany

9.4.2. France

9.4.3. United Kingdom

9.4.4. Spain

9.4.5. Others

9.5. Middle East and Africa

9.5.1. Saudi Arabia

9.5.2. UAE

9.5.3. Others

9.6. Asia Pacific

9.6.1. China

9.6.2. Japan

9.6.3. South Korea

9.6.4. India

9.6.5. Thailand

9.6.6. Taiwan

9.6.7. Others

 

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix

 

11. COMPANY PROFILES

11.1. Eli Lilly and Company

11.2. AbbVie, Inc.

11.3. Novartis AG

11.4. Bristol Myers Squibb

11.5. F.Hoffmann-La Roche Ltd

11.6. Johnson & Johnson Services, Inc.

11.7. Amgen Inc.

11.8. Merck & Co. Inc.

11.9. AstraZeneca PLC

Eli Lilly and Company

AbbVie, Inc.

Novartis AG

Bristol Myers Squibb

F.Hoffmann-La Roche Ltd

Johnson & Johnson Services, Inc.

Amgen Inc.

Merck & Co. Inc.

AstraZeneca PLC